Working Together For Personalized Medicine
Our goal is to increase the pace of commercialization for our existing Breast Cancer Test Suite, apply our model to other cancers, and eventually expand our product offering using the latest in molecular diagnostic platforms and technologies.
We currently have collaborations with over 50 cancer research institutes and hospitals worldwide. Several of our collaborating research institutes have well-annotated clinical tissue banks, providing us additional opportunities to discover and validate new gene signatures or biomarkers in breast and other areas of cancer.
Alliances With Pharmaceutical Companies
In addition to our collaborations with certain major international pharmaceutical companies under the auspices of the MINDACT and
I-SPY2 trials, we also collaborate directly with multiple pharmaceutical companies to explore development of new companion diagnostics for investigational cancer drugs.
We believe prospectively designed clinical studies provide the optimal data for development of our new products. A prospective study follows a group of patients with a particular form of cancer over time, who differs with respect to certain factors under investigation, to determine how these factors affect outcomes. We are currently participating in three major prospective clinical studies, MINDACT (breast cancer),
I-SPY2 (breast cancer) and PARSC (colon cancer), all of which are utilizing our MammaPrint® or ColoPrint® assay to pre-select patient groups for particular cancer treatments. Currently, the initial results of our MINDACT study were released at the 2016 AACR Annual Meeting.
Furthermore, we are participating in another prospective study to determine the impact of the MammaPrint assay on therapy decisions, the PRIMe study. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 672570.
Biomarkers For Pathway-targeted Therapies
The identification of crucial signaling pathways has led to the development of targeted drugs designed to inhibit these pathways. We have gathered gene expression and gene mutation data on thousands of colon cancer and breast cancer tissue samples, and we can use this data in our discovery projects on particular genetic pathway signatures, seeking to identify multiple key drivers of cancer cell behavior in various forms of cancer. We have begun collaborations with certain major international pharmaceutical companies and academic partners to identify new biomarkers and develop new tests for predicting response to these targeted therapies in the treatment of breast, colon and lung cancer. In the course of these efforts, we have begun to develop more sophisticated molecular diagnostics, integrating multiple diagnostic strategies, which we believe will lead to a new generation of multi-index tests in molecular cancer diagnostics.
Collaborative Development: Patient Sample To Diagnosis Process Enhancement
Our business is built on the core competencies of our founders’ world-renowned research and clinical experience in the field of genomics. Agendia’s culture is unique in terms of its unbiased scientific approach, pairing the optimum methodologies with disruptive technologies, to achieve ground-breaking, clinically meaningful results. We apply a “best in class” approach to maintain a leadership position in the rapidly evolving field of molecular diagnostics. We are committed to providing accurate, clinically relevant diagnostic assays to physicians and their patients.
Two of our founders, Professors Bernards and van’t Veer, are recognized world leaders in the field of molecular diagnostics and hold academic positions at leading comprehensive cancer centers (the Netherlands Cancer Institute and the University of California at San Francisco, respectively). We believe these appointments place us in an excellent position to partner with the academic world to develop molecular diagnostics discovery programs. We also participate in a number of European research networks funded by the European Union: RATHER and COLTHERES. We believe our participation in these networks, our strategic alliances with leading academic consortia as well as with large international pharmaceutical companies will contribute to our ability to develop new molecular diagnostic tests in breast cancer and other cancer areas, and further advance our research and development pipeline.
For more information, contact Agendia Business Development.